Completed NA INTERVENTIONAL 1-arm NCT00226317

Aripiprazole in the Treatment of Bipolar Depression

Phase 4 Study: An Open Prospective Study of the Safety and Effectiveness of Aripiprazole in the Treatment of Bipolar Depression

Sponsor: Bristol-Myers Squibb

Conditions Bipolar Disorder

Interventions Aripiprazole

Updated 6 times since 2017 Last updated: Apr 17, 2017 Started: Apr 30, 2004 Primary completion: Dec 31, 2007 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Bipolar Disorder and is currently completed. Bristol-Myers Squibb leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
May 2017 — Jun 2018 [monthly]

Completed NA

Status: Unknown Status → Completed

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Unknown Status NA

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Cambridge Health Alliance

Data source: Cambridge Health Alliance

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cambridge, United States